Paul A. Friedman, M.D.'s holdings in Madrigal Pharmaceuticals have seen noteworthy changes. Back in 2019, his investments peaked at approximately $41.20 million. Over the next year, fluctuations varied significantly, reaching around $46.55 million in July 2020, before dropping to $31.87...

Paul A. Friedman, M.D.'s holdings in Madrigal Pharmaceuticals have seen noteworthy changes. Back in 2019, his investments peaked at approximately $41.20 million. Over the next year, fluctuations varied significantly, reaching around $46.55 million in July 2020, before dropping to $31.87 million in March 2020. In January 2023, his holdings surged to an impressive $242.63 million, showing his significant stake in the company's future. Since then, the value of his holdings has seen ups and downs; for instance, in December 2023, his holdings were valued at about $170.87 million. This volatility reflects the dynamic nature of the biotech market and underscores the risk and reward for executives deeply invested in their companies' stock.